Clinical trial
Rapamycin vs Methotrexate in Diffuse SSc
NCT00241189 · University of California, Los Angeles, Other · Completed
Key facts
| NCT number | NCT00241189 |
|---|---|
| Title | Rapamycin vs Methotrexate in Diffuse SSc |
| Official title | A 48-week, Double-blind, Randomized, Parallel Phase I/II Study of Oral Rapamycin Versus Methotrexate in Systemic Sclerosis (Scleroderma) |
| Lead sponsor | University of California, Los Angeles, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Sclerosis |
| Intervention type | Drug |
| Interventions | rapamycin, methotrexate |
| Enrollment | 17 |
| Start date | Aug 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | Apr 11, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: